Andrew Aromando - 28 Apr 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Role
Chief Operating Officer
Signature
/s/ Sonja Nelson, Attorney-in-Fact for Andrew Aromando
Issuer symbol
N/A
Transactions as of
28 Apr 2023
Net transactions value
$0
Form type
4
Filing time
05 May 2023, 16:10:11 UTC
Next filing
07 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMAM Stock Option (right to buy) Award $0 +2,600,000 $0.000000 2,600,000 28 Apr 2023 Ordinary Shares 2,600,000 $1.38 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2 Grant awarded as an inducement grant in connection with the Reporting Person's appointment as Chief Operating Officer of the Issuer.
F3 Twenty-five percent of the Ordinary Shares subject to the option vested on April 28, 2024, and the remainder vests in thirty-six equal monthly installments following such date.
F4 The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.